Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesRadiology/Diagnostic ImagingWPS Health Insurance MRI CT PET Prior Auth Update …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedWPS Health InsurancePolicy N/A

    High‑tech diagnostic imaging (MRI, CT, PET) coverage and prior authorization updates

    Customize your policy alerts

    Sign up for all WPS Health Insurance policy alerts

    Know when WPS Health Insurance releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity indications, limits, and prior authorization requirements for advanced imaging modalities (CT, MRI, PET) and related services for WPS Health Insurance members; affects providers requesting imaging services and utilization management teams.

    Policy Summary
    PayerWPS Health Insurance
    PolicyHigh‑tech diagnostic imaging (MRI, CT, PET) coverage and prior authorization updates
    Policy CodePolicy N/A
    Change TypeMultiple material updates (prior auth additions/removalsclinical criteria added/modified)
    Effective DateJan 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization for all CT scans beginning 1/1/26.
    SourceLink
    POLICY UPDATE CHANGES

    All Computed Tomography (CT) scans will require prior authorization effective 1/1/26.

    Prior Authorization requirement for Spinal Manipulation Treatments and Chiropractic Treatments services was removed.

    MRI indications expanded or clarified across multiple body sites (e.g., abdomen iron overload, MR elastography for fibrosis, breast, pelvis, extremity trauma, TMJ, internal auditory canal, pediatric cerebral palsy one‑time scan).

    Repeat MRI within 6 months will be reviewed case‑by‑case and requires submission of most recent imaging report plus one of specified justifications to be approved.

    PET solitary pulmonary nodule must measure ≥ 8 mm to be considered.

    Use of any FDG tracer for evaluation of prostate cancer is considered experimental, investigational and unproven.

    Epidural injection limits changed to single level for interlaminar ESI and other injection limit revisions.

    Intraarticular (IA) facet injections considered medically necessary only when specified medication and PT trials and one of enumerated conditions are documented.

    Genetic and genomic testing (including multigene panels, WES/WGS) require prior authorization and are generally considered experimental/investigational unless proven clinically useful.

    Neuropsychological testing exceeding 10 hours will be denied as not medically necessary.

    Large list of devices and procedures added to Experimental/Investigational/Unproven list; see policy for specifics.

    Tumor treating fields (TTFT) coverage limited to newly diagnosed GBM only; continued use requires in-person re-evaluation between day 60 and 91 and Medical Director review every 3 months.

    Prior authorization required for PT/OT/ST (PA after 10 visits for PT; after 8 visits for other therapies) and reimbursement limited to one hour per date of service.

    Replacement of a prosthesis limited to no sooner than every three years; replacement due to irreparable wear may require 5 years and warranty documentation.

    1/1/26CT prior authorization effective date
    ≥8 mmPET SPN threshold
    6 monthsRepeat MRI justification window
    RemovedSpinal manipulation PA
    PAGenetic testing requirement
    10Neuropsych testing hour limit

    Medical Necessity and Coverage Criteria

    MRI Abdomen — iron overload

    Evaluation of iron overload in the abdomen.

    Iron overload indications: Evaluation of iron overload (e.g., hereditary hemochromatosis) when known or suspected.

    MR Elastography indications

    MR elastography for assessment of hepatic fibrosis in chronic liver disease when iron overload is not moderate/severe or when transient elastography is unavailable/indeterminate.

    MR elastography scenario 1: Chronic liver disease (excluding NAFLD) with need to assess for advanced fibrosis or cirrhosis AND EITHER patient BMI >= 30 OR vibration‑controlled transient elastography (VCTE) is unavailable, contraindicated, or yields indeterminate results.BMI >= 30

    MR elastography performed only when no moderate or severe hepatic iron overload documented.

    Policy Summary
    PayerWPS Health Insurance
    PolicyHigh‑tech diagnostic imaging (MRI, CT, PET) coverage and prior authorization updates
    Policy CodePolicy N/A
    Change TypeMultiple material updates (prior auth additions/removalsclinical criteria added/modified)
    Effective DateJan 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization for all CT scans beginning 1/1/26.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaServices Considered Not Medically Necessary / ExperimentalSpecific Covered Indications by ModalityFrequency, Interval and Quantity LimitsCodes, Thresholds and Short Data PointsPrior Authorization, Documentation and Billing ActionsContrast and Imaging Modality GuidanceKey Definitions and TermsPrior Authorization RequirementsBackground and ScopePolicy Revision History
    MR elastography scenario 2: Nonalcoholic fatty liver disease (NAFLD) when hepatic fibrosis or cirrhosis is known or suspected.

    MR elastography performed only when no moderate or severe hepatic iron overload documented.

    Brain MRI indications (selected additions)

    Selected brain MRI indications including tumor surveillance and one‑time neurodegenerative evaluation.

    Meningioma surveillance: Known or suspected meningioma managed by observation: imaging at 3, 6, and 12 months, then every 6 months for 5 years, then every 1–3 years as clinically indicated.

    Surveillance schedule described in policy.

    Neurodegenerative / cognitive evaluation: One‑time MRI evaluation for cognitive impairment, memory loss, or changes in mental status of unknown etiology, including unexpected changes in existing symptoms or clinical course.
    Functional brain MRI for pre-surgical planning: Functional MRI for pre-surgical planning when used to identify eloquent cortex for brain tumor resection (except temporal tumors), or for epilepsy (except temporal neocortical epilepsy), or for vascular malformations.

    Repeat MRI within 6 months

    Repeat MRI of the same anatomic site within 6 months is reviewed case‑by‑case and requires submission of the most recent imaging report plus one qualifying justification.

    Repeat MRI allowable justifications: Approval requires submission of the most recent imaging report and ONE of the following: (a) prior testing was inconclusive or short‑term follow‑up imaging was recommended; (b) clinical documentation of progressive worsening or new physical exam findings that will alter management; (c) interval surgery with suspected complication or significant new trauma to the anatomic region.6 months

    Case‑by‑case review; most recent imaging report must be submitted.

    MRI Extremity/Trauma and musculoskeletal indications

    Extremity and trauma MRI indications and selected musculoskeletal scenarios.

    Non‑contrast MRI for trauma/fracture: Non‑contrast MRI is medically necessary for suspected acute or occult fractures including scaphoid, talus, tarsal navicular, and great toe sesamoid; and for post‑operative evaluation when other imaging, physical exam, or lab findings suggest infection, delayed union/nonunion, or other surgical/procedural complication.

    Non‑contrast MRI preferred for specified acute/occult fractures.

    Plantar fasciitis imaging precondition: MRI for plantar fasciitis considered when symptoms persist after failure of at least 6 months of treatment including at least two of: mechanical deweighting, foot orthosis, night splints, taping, or manual therapy.6 months

    Orthotics and conservative measures should be documented.

    Pre-operative evaluation: MRI may be used for pre-operative planning for musculoskeletal procedures when indicated.

    MRI Pelvis indications (selected additions)

    Selected pelvic MRI indications including prostate cancer staging, biopsy planning, and other pelvic conditions when CT is inconclusive or contraindicated.

    Prostate MRI staging/biopsy guidance: Pelvic MRI for staging of prostate cancer for unfavorable intermediate, high, or very high‑risk groups and for MRI guidance when anatomic guidance is needed for biopsy. Repeat MRI subsequent to the MRI that detected the nodule for MRI/TRUS fusion biopsy is not medically necessary.

    Refer to MRI/US/CT 3D rendering policy for reconstructions.

    Hernia / athletic pubalgia: Suspected athletic pubalgia (sports hernia) with persistent exertional groin pain, no ventral/inguinal hernia on exam, and failure of at least 4 weeks of conservative treatment when radiographs are nondiagnostic.4 weeks
    Pelvic MRI when CT inconclusive/contraindicated: Pelvic MRI medically necessary for unexplained fever with leukocytosis after surgery and no other source identified, fever with signs suggesting pelvic source, or unexplained weight loss >10% over 6 months when CT is inconclusive or contraindicated.weight loss >10% over 6 months

    PET scan indications and exclusions

    PET scan indications and explicit exclusions.

    SPN PET criteria: Non‑oncologic PET scan evaluation of a solitary pulmonary nodule (SPN) is considered when the SPN measures >= 8 mm in total size.>= 8 mm
    PET exclusions: Use of any FDG tracer for evaluation of prostate cancer is considered experimental, investigational and unproven and is not covered.

    Insufficient evidence to support effectiveness for prostate cancer evaluation with FDG PET.

    TMJ MRI indications

    MRI indications for evaluation of temporomandibular joint (TMJ).

    TMJ MRI indications: Evaluation of TMJ with clinical suspicion of: (a) trauma requiring assessment of meniscal position/integrity when radiograph/CT indeterminate; (b) preoperative or postoperative planning; (c) moderate-to-severe TMJ pain worsened by jaw use after completion of >=4 weeks of conservative treatment; (d) TMJ neoplasm/cancer; or (e) inflammatory arthropathy (e.g., RA, psoriatic arthritis, juvenile idiopathic arthritis, ankylosing spondylitis).>= 4 weeks conservative therapy for pain indication

    Plain X‑ray or CT should be indeterminate for trauma/meniscal assessment indication.

    Pain procedure coverage criteria

    Coverage criteria for epidural and facet injection therapies, including prerequisites and qualifying conditions.

    Subsequent epidural injection prerequisites: Prior epidural injection must have produced at least 50% improvement in pain and function and at least two weeks must have passed since the previous injection; if these are not met, a different approach or level may be attempted (usually within 3–7 days).>=50% improvement; >=2 weeks
    IA facet injection prerequisites: Completion of a 6‑week trial of medications (e.g., anti‑inflammatories, muscle relaxants, analgesics, opioids, gabapentin/pregabalin) within the last 12 months AND completion of a 6‑week trial of physical therapy or chiropractic care (performed after the current episode began) within the last 12 months.6 weeks trials

    These are required before IA injection consideration.

    IA facet injection qualifying conditions: One of the following must be documented: suspected inflammatory facetogenic pain from systemic inflammatory arthropathy; contraindication to denervation; individual at high risk for RFN complications; or evidence of nerve root compression from a facet synovial cyst or large effusion on advanced imaging performed within the previous 12 months that correlates with clinical findings.imaging within 12 months

    Cyst aspiration/rupture may be repeated once within 12 months only if prior relief >=50% for >=3 months.

    Subsequent Epidural Steroid Injection (ESI) Coverage

    Subsequent interlaminar epidural steroid injections (ESI) coverage requirements.

    Subsequent ESI criteria: 1) Prior injection produced >=50% improvement in pain and function but symptoms returned; 2) At least 2 weeks have passed since the previous injection.>=50% improvement

    If criteria not met, a different approach or level may be attempted (usually within 3–7 days).

    Intraarticular Facet Joint Injection

    Intraarticular facet joint injections are covered only when baseline conservative trials are completed and at least one qualifying condition is documented.

    IA facet injection baseline requirements: Completion of a 6‑week trial of medications (anti‑inflammatories, muscle relaxants, analgesics, opioids, gabapentin or pregabalin) within the last 12 months AND completion of a 6‑week trial of physical therapy or chiropractic manipulation (after the current episode began) within the last 12 months.6-week trials

    These preconditions must be documented.

    IA facet injection qualifying conditions: One of the following must be documented: (a) suspected inflammatory facetogenic pain due to systemic inflammatory arthropathy; (b) denervation contraindicated; (c) individual at high risk for RFN complications; (d) evidence of nerve root compression from a facet synovial cyst or large effusion on MRI/CT within previous 12 months correlating with clinical findings.N/A

    Cyst aspiration/rupture repeat rules: may be repeated once within 12 months only if prior relief >=50% for >=3 months.

    Facet Joint Injection Limits

    Frequency and level limits for intraarticular (IA) facet joint injections when covered.

    Facet IA frequency limits: Maximum of four (4) IA facet joint sessions per covered spinal region (cervical or lumbosacral) per rolling 12 months; per session, maximum of two (2) levels (unilateral or bilateral).4 per 12 months; max 2 levels per session

    Repeat at same anatomic site allowed only if prior injection provided >=50% reduction in pain with functional improvement lasting at least 3 months.

    Genetic and Molecular Testing

    Genetic, genomic, molecular, and pharmacogenetic testing require prior authorization and are limited based on analytic/clinical validity and clinical utility.

    Prior authorization required: All genetic, genomic, pharmacogenetic, molecular genetic, multigene panels, WES, WGS and related testing require prior authorization BEFORE testing is completed.prior authorization

    Determination based on analytical/clinical validity and clinical utility.

    Panel and broad testing: Multigene test panels, whole exome sequencing, whole genome sequencing, genome‑wide association studies, and broad molecular profiling are generally considered experimental, investigational and unproven and will be denied unless prior authorization review determines they are medically necessary.N/A

    When panels include genes irrelevant to the indication, those genes/tests will be considered not medically necessary.

    Repeat CGP limitations: Repeat comprehensive genomic profiling (tissue or liquid) is not medically necessary if previously performed on the same primary tumor type except in settings of unexpected treatment results or loss of prior treatment response suggesting tumor evolution; simultaneous liquid biopsy with solid tumor testing is not medically necessary.N/A

    Neuropsychological Testing

    Neuropsychological testing coverage with limits.

    Complicated ADHD indication: Complicated ADHD testing covered when: (1) specific neurocognitive/behavioral deficits related to ADHD need evaluation; AND (2) testing is recommended by a physician and is related or secondary to a known or suspected organic/medical condition (e.g., TBI, CNS infection, intractable seizure disorder, cancer treatment effects, genetic disorders, inborn errors of metabolism, stroke, hypoxic‑ischemic encephalopathy).

    More than 10 hours of testing is not standard of care and will be denied as not medically necessary.

    Custom orthoses coverage

    Custom orthoses (AFO/KAFO), knee orthoses, and foot orthotics are covered when detailed treating documentation supports necessity over prefabricated devices.

    Custom orthoses: Member cannot be fit with a prefabricated AFO/KAFO; OR condition necessitating the orthosis is expected to be permanent or longstanding (>6 months); OR need to control knee/ankle/foot in more than one plane; OR documented neurological, circulatory, or orthopedic status requiring custom fabrication to prevent tissue injury; OR member has a healing fracture lacking normal anatomical integrity or anthropometric proportions.>6 months when applicable

    Treating physician documentation required to support medical necessity over prefabricated orthosis.

    Custom knee orthoses

    Custom fabricated knee orthoses coverage criteria.

    Custom knee orthoses: Documented physical characteristic requiring custom fabrication instead of a prefabricated knee orthosis (examples: contracture/deformity interfering with fit, abnormal limb contour, minimal muscle mass for suspension).

    Medical record must support necessity or request will be denied as not medically necessary.

    Custom foot orthotics

    Custom foot orthotics coverage criteria.

    Custom foot orthotics: (1) Arch, heel, or other foot pain; AND (2) foot condition such as juvenile idiopathic arthritis, pes cavus, plantar fasciitis with failed conservative measures (activity adjustment, NSAIDs, prefabricated orthotics, stretching) with symptoms present for >=1 month; OR posterior tibial tendon dysfunction (stage I or II) or rheumatoid arthritis.>=1 month when applicable

    Orthotics should not be first‑line therapy; documentation of failed conservative care required.

    Spinal orthoses

    Custom fabricated spinal orthoses coverage requirements.

    Custom spinal orthoses: Detailed documentation in the treating practitioner's records must support the medical necessity of a custom fabricated spinal orthosis rather than a prefabricated device; orthotist functional evaluation and method of custom fabrication should be available upon request.

    Reasonable useful lifetime of custom fabricated orthosis is 3 years.

    TMJ coverage criteria

    TMJ diagnostic and treatment coverage criteria and conservative therapy prerequisites.

    TMJ general coverage: Condition must be caused by congenital, developmental, or acquired deformity/disease/injury; radiographic evidence of significant joint abnormality; procedure/device reasonable and appropriate; primary purpose to control or eliminate infection, pain, disease or dysfunction; services not for cosmetic/elective dental care.

    Benefits include arthrocentesis, arthroscopy, arthroplasty, arthrotomy and appropriate non‑surgical treatments.

    TMJ conservative therapy requirement: Nonsurgical management including 3–6 months of appropriate conservative care (physical therapy, pharmacotherapy, behavioral therapy, manipulation, trigger point injections) should be attempted prior to more complicated surgeries; for TMJ PT/OT visits, a total of four visits related to TMJ are considered medically necessary.3-6 months

    Prolonged (>6 months) intra‑oral appliance use not considered medically necessary without individual case review; one appliance every 2 years.

    Arthrocentesis / arthroscopy criteria: Arthrocentesis medically necessary when imaging/clinical exam demonstrate anchored disc phenomenon, anterior disc displacement without reduction and without effusion, osteoarthritis without fibrosis, open lock, hemarthrosis, or pain persists despite >=6 months of noninvasive therapies. Therapeutic arthroscopy necessary when MRI or other imaging confirms adhesions, fibrosis, degenerative joint disease or internal derangement requiring internal modification.>=6 months for failure of noninvasive therapy where specified

    Open procedures and joint replacement allowed when imaging documents severe joint destruction and conservative measures failed.

    Tumor treating fields (TTFT) for GBM

    Tumor treating fields (TTFT) coverage for newly diagnosed glioblastoma multiforme (GBM) including initiation and continued coverage requirements.

    TTFT initial coverage: All of the following must be met: (1) histologically confirmed newly diagnosed supratentorial GBM (WHO grade IV); (2) received initial maximal debulking surgery when feasible followed by chemotherapy and radiotherapy; (3) TTFT initiated within 7 weeks from last dose of concomitant chemotherapy or radiotherapy; (4) no evidence of progression by RANO criteria; (5) Karnofsky Performance Score >= 70; (6) member will use TTFT an average of 18 hours per day.average 18 hours/day
    TTFT continued coverage: No sooner than day 60 and no later than day 91 after initiating therapy, treating practitioner must conduct an in‑person clinical re‑evaluation and document objective evidence of adherence (average 18 hours/day) and benefit; if re‑evaluation occurs after day 91 but documents benefit, continued coverage commences from date of that re‑evaluation.day 60-91

    Continued use beyond initial period requires Medical Director review every 3 months.

    TTFT limitation: Use of TTFT for any indication other than newly diagnosed GBM is denied as not medically necessary.

    Medical Director review every 3 months for continued use.

    Prosthesis coverage criteria

    General prosthesis coverage criteria applicable to upper and lower extremity prostheses.

    General prosthesis criteria: Care prescribed by a qualified clinician per state law; prosthesis will significantly improve or restore mobility‑related activities of daily living (MRADLs); determination based on physical exam; prosthesis provided within six months of prescription; prosthetic services performed by duly licensed/certified provider; services require licensed/certified prosthetist or direct supervision as permitted by state law; prosthetist certification/licensure in good standing with ABC or BOC or state license.provided within 6 months of prescription

    Functional ability classification (K‑level) used to assess medical necessity.

    General criteria for prosthesis coverage

    Covered when ALL of the following general criteria are met:

    General prosthesis checklist: 1) Care prescribed by a qualified clinician; 2) Prosthesis will significantly improve/restore MRADLs; 3) Participating clinician determined prosthesis allows ADLs based on exam; 4) Prosthesis provided within six months of prescription; 5) Prosthetic services performed by duly licensed/certified provider; 6) Services require licensed/certified prosthetist or under their direct supervision; 7) Prosthetist in good standing with ABC or BOC or state licensure.

    Lower limb prostheses (general)

    Lower limb prostheses coverage logic including microprocessor device considerations.

    Lower limb prosthesis types: A) Mechanical (nonpowered/non‑microprocessor) single axis/fluid swing/stance addition (L5828) is medically necessary when individual is functional level 3 or greater; OR B) Microprocessor‑controlled lower limb prosthetics (including required additions/components) are medically necessary when individual is functional level 3 or greater AND any listed device‑specific indications are met; OR C) Microprocessor‑controlled devices are not medically necessary for other indications.K3

    See specific device‑level criteria for knees/ankles.

    Microprocessor knee eligibility

    Eligibility criteria for microprocessor knee devices (HCPCS L5856/L5857/L5858).

    Microprocessor knee criteria: All of the following must be met: (a) knee disarticulation or transfemoral amputee; AND (b) need for daily long‑distance ambulation at variable rates (>400 yards); AND (c) need for regular ambulation on uneven terrain or regular stair use; AND (d) adequate cardiovascular, neuromuscular, and pulmonary reserve for faster ambulation; AND (e) demonstrates ability to ambulate faster with a standard swing/stance control knee; AND (f) cognitive ability to master gait sequencing and device care; AND (g) functional level is K3 or K4.>400 yards

    All conditions required for microprocessor knee eligibility.

    Powered prosthetic knee coverage

    Powered microprocessor knee (HCPCS L5859) additional criteria — ALL must be met.

    Powered microprocessor knee criteria: All of the following: (1) individual already has a swing and stance phase microprocessor‑controlled knee (L5856); (2) individual is functional level K3 only; (3) documented comorbidity of the spine and/or sound limb affecting hip extension and/or quadriceps function that impairs K3 function with the microprocessor knee alone.K3

    Device is not intended for high‑impact/sports use.

    Microprocessor device prerequisites and trial

    Prerequisites and trial requirements for microprocessor‑controlled prosthetic devices.

    Microprocessor device prerequisites: I) Individual willing to ambulate and current activities exceed capabilities of standard prosthesis; II) has used a standard lower limb prosthesis independently for minimum 3 months; III) medical/PT/prosthetist records document device will enable reaching K3 within 3 months, absence of prohibitive comorbid conditions, gait analysis showing faster ambulation than current prosthesis, and appropriate patient weight/height for device.3 months

    All prerequisites required prior to approval.

    Upper limb myoelectric prosthesis

    Upper limb myoelectric prosthesis coverage criteria.

    Upper limb myoelectric criteria: All of the following must be met: (1) standard body‑powered prosthesis is insufficient or patient cannot use it; (2) patient is >= 2 years old; (3) unilateral trans‑radial or trans‑humeral deficiency with sufficient proximal musculature microvolt threshold to operate a myoelectric device; (4) cognitive ability to operate and participate in training; (5) able to tolerate prosthesis weight; (6) no underlying neuromuscular disease.age >= 2

    All conditions required.

    Repair and replacement policy

    Repair and replacement rules for prostheses and DME.

    Repair vs replacement: Replacement limited to no sooner than every three (3) years after purchase; replacement medically necessary when change in physiological condition/functional level or device condition justifies replacement; replacement required if repair cost exceeds replacement and not covered under warranty; repairs covered for accidental damage or extensive wear; replacement of member‑owned DME due to irreparable wear cannot be less than five (5) years.3 years; 5 years

    Warranty documentation required with request.

    Services Considered Not Medically Necessary / Experimental

    Use of any FDG tracer for evaluation of prostate cancer is considered experimental, investigational and unproven and therefore not covered due to insufficient evidence supporting clinical usefulness.

    Intraarticular (IA) facet joint injections performed for indications that do not meet the policy prerequisites will be denied. Required documentation includes completion of a 6‑week trial of medications within the prior 12 months and a 6‑week trial of physical therapy or chiropractic care during the current episode, plus one of the qualifying conditions (for example, inflammatory arthropathy or imaging evidence of nerve root compression from a facet synovial cyst). Requests without these trials or without correlating advanced imaging within 12 months will not meet medical necessity criteria.

    Replacement of an intra‑oral temporomandibular (TMJ) appliance that is lost, missing, or stolen is explicitly not covered. Additionally, prolonged continuous use of an intra‑oral appliance beyond 6 months is not considered medically necessary without individual case review documenting ongoing clinical need.

    The policy lists multiple modalities that are removed from coverage or considered experimental/not medically necessary in the context of spinal manipulation/chiropractic care. Examples include low‑level laser therapy (LLLT), deep laser therapy, far infrared therapy, cryotherapy, low‑intensity continuous ultrasound, massage therapy, infrared therapy/services, and TENS. These modalities are either removed from covered modalities or identified as experimental/investigational and will be denied when billed for extraspinal manipulation or maintenance chiropractic care.

    A PET scan using an FDG tracer for evaluation of prostate cancer is considered experimental, investigational and unproven and therefore not covered. For other PET indications, such as solitary pulmonary nodule evaluation, the policy retains a size threshold (see criteria) but FDG tracer use specifically for prostate cancer is excluded.

    Computerized or computer‑based cognitive testing systems (for example, Creyos, Cognitrax, Neurotrax) are considered experimental, investigational and unproven. In addition, formal neuropsychological testing that exceeds 10 hours will be denied as not medically necessary because it exceeds the policy's standard‑of‑care testing limits.

    Cervical spinal cord stimulation and certain spinal cord systems are listed as experimental, investigational and unproven for many indications not explicitly approved by the policy. The policy also identifies specific device systems (for example, the Freedom Spinal Cord Stimulator System) and non‑epilepsy vagus nerve stimulator use as not supported by current evidence and therefore not covered.

    Tumor treating fields (TTFT) are covered only for newly diagnosed glioblastoma multiforme (GBM) under the policy’s defined criteria. Use of TTFT for other indications is explicitly not medically necessary and will be denied.

    Requests for custom fabricated orthoses must include detailed treating practitioner documentation demonstrating why a prefabricated orthosis is insufficient. Custom orthoses lacking this documentation will be denied as not medically necessary.

    Microprocessor‑controlled prosthetic devices are approved only when the individual meets the policy’s specific functional and clinical prerequisites (e.g., K‑level requirements and trial of a standard prosthesis). Use of a microprocessor prosthetic for limited home or community ambulation tasks (for example, occasional stair climbing at home) is considered not medically necessary and will be denied.

    When intraarticular (IA) facet injections do not meet the policy’s documented prerequisites (missing the required 6‑week medication and 6‑week PT/chiropractic trials, lack of qualifying imaging correlation, or failure to document prior benefit), claims for additional IA sessions or higher numbers of treated levels may be denied. The policy limits coverage to a maximum of 4 IA facet joint sessions per covered spinal region per rolling 12 months and a maximum of 2 levels per session; absence of required documentation is a basis for non‑coverage.

    Intraarticular (IA) facet joint injections without the required conservative therapy documentation (the 6‑week medication trial and 6‑week physical therapy or chiropractic trial) or without advanced imaging correlating a qualifying condition (for example, nerve root compression from a facet synovial cyst on MRI/CT within the prior 12 months) are considered not covered. The policy also states that IA injections are not medically necessary for indications other than those explicitly listed.

    Prolonged (> 6 months) application of intra‑oral TMJ appliances without supporting case review documentation is not covered. Replacement of an intra‑oral appliance that is lost, missing, or stolen is also not covered under the policy.

    Low‑level laser therapy, TENS, and a range of other modalities are listed as not medically necessary or experimental/investigational when used as part of chiropractic or spinal manipulation services. The policy specifically removes these modalities from covered services and identifies them in the Experimental/Investigational/Unproven list, which will lead to denial when billed for extraspinal manipulation or maintenance care.

    Specific Covered Indications by Modality

    inv-87: MR Elastography for chronic liver disease when fibrosis assessment needed and iron overload absent or when elastography unavailable/indeterminate.

    MR Elastography for chronic liver disease when fibrosis assessment needed and iron overload absent or when elastography unavailable/indeterminate.

    MR Elastography covered scenario: MR elastography is medically necessary for chronic liver disease (excluding NAFLD) to assess for advanced fibrosis/cirrhosis when the patient has BMI >=30 OR vibration‑controlled transient elastography is unavailable, contraindicated, or indeterminate; and for NAFLD when hepatic fibrosis or cirrhosis is known or suspected. Moderate or severe hepatic iron overload must not be documented.BMI >= 30

    inv-88: Non‑contrast MRI for trauma/fracture and post‑operative complications.

    Non‑contrast MRI is medically necessary for select acute/occult fractures and certain postoperative complications.

    Non‑contrast MRI trauma/fracture: Non‑contrast MRI is medically necessary for suspected acute or occult fractures such as scaphoid, talus, tarsal navicular, and great toe sesamoid; and for postoperative evaluation when other imaging, exam, or labs suggest infection, delayed union/nonunion, or surgical complication.

    inv-89: Pelvic MRI for prostate cancer staging and biopsy planning.

    Pelvic MRI for prostate cancer staging and for guidance when biopsy anatomic localization is needed.

    Prostate MRI staging/biopsy planning: Pelvic MRI is medically necessary for staging in unfavorable intermediate, high, or very high‑risk prostate cancer per NCCN and when anatomic guidance is needed for biopsy; repeat MRI after the MRI that detected the nodule for MRI/TRUS fusion biopsy is not medically necessary.

    inv-90: Facet IA injection for nerve root compression from synovial cyst/effusion

    IA facet injection for nerve root compression due to facet synovial cyst or large effusion requires imaging confirmation.

    Imaging-confirmed facet cyst/effusion: Evidence of nerve root compression from a facet synovial cyst or large effusion must be demonstrated on MRI or CT performed within the previous 12 months that correlates with clinical findings to support intraarticular (IA) facet injection for nerve root compression.imaging within 12 months

    Associated moderate‑to‑severe radicular pain and functional limitations required; cyst aspiration/rupture repeat rules apply.

    inv-91: Imaging-confirmed TMJ pathology to justify surgical intervention

    Imaging must confirm TMJ pathology before proceeding to surgical interventions.

    Imaging confirmation for TMJ surgery: MRI or other imaging must confirm adhesions, fibrosis, degenerative joint disease, internal derangement (e.g., severe disc displacement with degenerative changes or perforation), scarring, or other pathologic joint change to justify arthroscopy, arthroplasty, arthrotomy, or joint replacement for TMJ.

    All nonsurgical therapies should be exhausted unless immediate surgery is clinically required.

    inv-92: Imaging/pathology confirmation for TTFT in newly diagnosed GBM

    Histologic confirmation and imaging criteria required for TTFT initiation in newly diagnosed GBM.

    GBM imaging/pathology: Histologically confirmed supratentorial GBM (WHO grade IV) is required prior to TTFT; initiation requires no evidence of progression by RANO criteria and prior maximal debulking surgery plus chemoradiation as specified.

    TTFT must be initiated within 7 weeks of last chemo/radiation dose and adherence documented for coverage.

    inv-93: Imaging related to spinal manipulation/chiropractic services

    Imaging for spinal manipulation and chiropractic services must be supported by history and physical exam.

    Imaging for spinal/chiropractic care: History and physical examination must support the rationale for imaging related to spinal manipulation or chiropractic services; full spine radiograph is medically necessary only for scoliosis.

    Therapy prior authorization rules apply separately.

    Frequency, Interval and Quantity Limits

    MRI — Repeat within 6 months
    Policy requirementRequests for repeat MRI of the same anatomic site within 6 months will be reviewed case-by-case and must include the most recent imaging report; approval requires one of: prior testing inconclusive/short-term follow-up recommended; progressive worsening/new findings that will alter management; or interval surgery/significant new trauma.
    Applicable periodWithin 6 months of prior MRI
    Documentation neededMost recent imaging report plus clinical justification matching one of the specified criteria
    MRI — Meningioma surveillance
    Surveillance scheduleFor known or suspected meningioma managed by observation only: imaging at 3 months, 6 months, and 12 months, then every 6 months for 5 years, then every 1–3 years as clinically indicated.
    IndicationMeningioma under observation (no immediate intervention)
    Clinical discretionAfter 5 years, interval imaging frequency may be extended to every 1–3 years based on clinical context
    Image‑guided injections — Facet IA session limits
    Maximum sessionsMaximum of 4 intraarticular (IA) facet joint sessions per covered spinal region per rolling 12 months
    Covered spinal regionsCervical or lumbosacral regions
    Repeat allowanceRepeat at same anatomic site allowed only if prior injection provided ≥50% pain reduction with functional improvement for at least 3 months
    Device therapy review — TTFT continued use
    Review intervalContinued tumor treating fields (TTFT) use requires Health Plan Medical Director review every 3 months
    Initial re-evaluation windowTreating practitioner must perform in-person re-evaluation between day 60 and day 91 after therapy initiation to document adherence and benefit
    Adherence evidenceObjective evidence of device adherence (see adherence threshold) must be submitted for continued coverage reviews
    Imaging necessity and full‑spine radiograph rules
    Medical necessity standardX-ray, CT or MRI is considered medically necessary only when the history and physical examination support the rationale for the imaging
    Full spine radiographFull spine radiograph is medically necessary only for evaluation of scoliosis
    Therapy linkageImaging ordered to support therapy or chiropractic care must be justified by history/physical; therapy PA rules apply separately

    Codes, Thresholds and Short Data Points

    Genetic testing (prior auth required)mixed
    affected codesGenetic/genomic test codes and panels requiring prior authorization
    Prosthetic HCPCS codes referencedHCPCS
    L5828Single axis, fluid swing and stance phase control lower limb addition
    L5973Ankle-foot prosthetic (microprocessor-controlled) for transtibial amputee
    L5856Knee prosthetic (microprocessor-controlled) — code listed
    L5857Knee prosthetic (microprocessor-controlled) — code listed
    L5858Knee prosthetic (microprocessor-controlled) — code listed
    L5859Endoskeletal knee-shin system with powered flexion/extension assist control (powered microprocessor knee)
    L5969Powered ankle/foot device (example code referenced as not medically necessary)
    SPN size threshold for PET
    Size thresholdSolitary pulmonary nodule (SPN) must measure ≥ 8 mm to be considered for PET evaluation
    ModalityNon‑oncologic PET for SPN
    Exclusion noteRefer to PET limitations for tracer-specific exclusions (e.g., FDG for prostate cancer)
    Facet IA sessions per spinal region (max)
    Maximum sessions per regionMaximum of 4 IA facet joint sessions per covered spinal region per rolling 12 months
    Per-session level limitPer session, a maximum of 2 levels (unilateral or bilateral) per spinal region may be treated
    Condition for repeatRepeat at same anatomic site allowed only if prior injection provided ≥50% pain reduction with functional improvement for at least 3 months
    Facet IA levels per session (max)
    Levels per sessionMaximum of 2 levels (unilateral or bilateral) per session per covered spinal region
    Regions coveredApplies to cervical and lumbosacral regions
    Denial riskExceeding per-session level limits may result in denial as not medically necessary
    TTFT daily adherence (hours/day)
    Adherence thresholdAverage use of 18 hours per day is required and must be documented for continued TTFT coverage
    Documentation timingEvidence of adherence must be documented at the in-person re-evaluation between day 60 and day 91 after initiation
    Exclusion for other indicationsTTFT use for indications other than newly diagnosed GBM is denied as not medically necessary
    DME single‑purchase limitation (3 years)
    Purchase limitationOne purchase of a given type of DME (including repair or replacement) is allowed every three years
    Applies toDurable medical equipment as defined by policy (member‑owned devices subject to replacement rules)
    Replacement exceptionsReplacement earlier than three years requires justification (e.g., change in physiological condition) and warranty documentation
    Daily ambulation distance for microprocessor knee candidacy
    Ambulation distance thresholdNeed for daily long‑distance ambulation greater than 400 yards is required for microprocessor knee candidacy
    Device contextApplies when considering microprocessor-controlled knee prostheses (HCPCS knee codes) for transtibial or transfemoral amputees as specified
    Functional levelMicroprocessor knee candidates must also meet functional level (K-level) and other criteria

    Prior Authorization, Documentation and Billing Actions

    Prior Authorization

    Genetic and genomic testing prior authorization

    All genetic, genomic, pharmacogenetic, pharmacogenomic, molecular genetic, mRNA, DNA, chromosome, telomere, single nucleotide polymorphism (SNP), gene sequencing, gene expression profiles, and gene-related panels, tests and analyses require prior authorization BEFORE testing is completed. Determination of coverage for panels is based on analytical/clinical validity and clinical utility; multigene panels are generally considered experimental/investigational unless prior authorization deems otherwise.

    • Prior authorization required BEFORE testing for all genetic/genomic/pharmacogenetic and related tests
    • Multigene panels generally denied as not medically necessary unless prior auth demonstrates clinical utility
    • Genetic counseling strongly recommended prior to testing
    Documentation Required

    Genetic testing prior authorization documentation

    When requesting genetic or genomic testing, include documentation supporting medical necessity and relevance of each gene tested to the member's diagnosis or management. Prior authorization reviewers will assess analytical/clinical validity, clinical utility, and relevance of individual genes within panels. Tests deemed experimental/investigational (e.g., genome-wide association studies, many pharmacogenetic panels) are typically denied.

    • Submit clinical indication, family/personal history, and how results will impact care
    • If individual gene codes are submitted from within a panel, include documentation for each gene's medical necessity
    • Include evidence of genetic counseling when available
    Prior Authorization

    TTFT prior authorization / documentation

    Tumor Treating Fields Therapy (TTFT) for newly diagnosed GBM requires prior authorization and strict documentation of initial and continued benefit. Continued coverage requires re-evaluation and objective adherence evidence within specified windows.

    • TTFT must be initiated within 7 weeks of last dose of chemo/radiotherapy for newly diagnosed GBM
    • Initial authorization: documentation of diagnosis, prior treatments, Karnofsky ≥70, and planned average use of 18 hours/day
    • Re-evaluation for continued coverage: in-person clinical re-evaluation between day 60 and day 91 after starting therapy
    • Objective evidence of adherence (average 18 hours/day) must be reviewed and documented by treating practitioner
    Documentation Required

    TTFT re-evaluation & adherence documentation

    For continued TTFT beyond the initial period, the treating practitioner must document clinical benefit via an in-person re-evaluation AND objective adherence evidence. If re-evaluation occurs after day 91 but demonstrates benefit and adherence, continued coverage may commence from the re-evaluation date. Recurrent GBM and indications other than newly diagnosed GBM are not covered.

    • In-person clinical re-evaluation by treating practitioner required (no sooner than day 60, no later than day 91)
    • Objective adherence evidence (average 18 hours/day) reviewed and documented
    • If re-evaluation after day 91 shows benefit/adherence, coverage may start from that date
    • Use of TTFT for recurrent GBM is denied
    Prior Authorization

    Injection level/repeat restrictions and epidural response requirements

    Subsequent epidural injections and facet procedures have response, timing, and repeat limits: prior response and minimum interval must be documented; injection levels per session are restricted.

    • Previous injection must have improved pain/function by ≥50% with return of symptoms to qualify for a subsequent injection
    • At least 2 weeks must have passed since the previous injection; if criteria not met, a different approach or level may be attempted (usually within 3–7 days)
    • Interlaminar epidural steroid injections limited to a single level per session
    • Facet (IA) injections: maximum of four sessions per covered spinal region per rolling 12 months; maximum of two levels per session per region
    • Facet joint injection repeat at same anatomic site allowed if prior injection provided ≥50% pain reduction with ≥3 months duration
    Documentation Required

    Facet IA documentation requirements and facet cyst aspiration documentation

    Intraarticular facet (IA) injection coverage requires documented conservative therapy trials and specific imaging/clinical findings. Facet cyst aspiration has its own imaging and repeat rules.

    • Patient must have completed a 6-week trial of medications (anti-inflammatories, muscle relaxants, analgesics, opioids, gabapentin/pregabalin) within the last 12 months
    • Patient must have completed a 6-week trial of physical therapy or chiropractic manipulation (after current episode onset) within the last 12 months
    • Must document one of the qualifying conditions (e.g., imaging-confirmed facet pathology)
    • Evidence of nerve root compression due to a facet synovial cyst/large effusion on MRI or CT within the previous 12 months is required for cyst aspiration
    • Cyst aspiration/rupture may be repeated once within 12 months only if prior aspiration produced ≥50% pain reduction for at least 3 months
    Denial Risk

    OSA procedures exclusion

    Certain OSA-related procedures are excluded as not covered or considered experimental; suppliers and clinicians must follow device coverage rules.

    • Minimally invasive tongue base reduction procedures for treatment of obstructive sleep apnea are considered experimental / not covered
    • Playing of wind instruments for treatment of sleep-related breathing disorders is not covered
    • PAP devices, oral appliances and hypoglossal nerve stimulators remain subject to existing DME/device coverage criteria and prior authorization where applicable
    Prior Authorization

    DME prior authorization and order/orthosis documentation requirements

    Durable Medical Equipment (DME) and TMJ items require prior authorization depending on dollar thresholds and plan benefits. New order and therapy documentation requirements apply for DME and prosthetics; custom orthoses require detailed treating-physician and orthotist documentation.

    • Prior authorization required for DME depending on dollar threshold; benefits limited to single purchase of a type of DME every three years
    • Standard Written Order (SWO) must include member name/ID, order date, description (or HCPCS/brand), quantity, treating practitioner name/NPI and signature, and be written prior to delivery
    • For custom fabricated orthoses, treating physician records must document why a custom device is required over a prefabricated orthosis and be corroborated by orthotist functional evaluation
    • Repairs versus replacements: repairs are part/ labor on base item; replacement due to significant change in condition requires documentation
    Documentation Required

    Conservative therapy requirements and prerequisites

    Conservative therapy prerequisites apply across several interventions (e.g., facet injections, custom orthoses, TMJ treatment, microprocessor-controlled prosthetics): document trials and failures of less invasive treatments before advanced/interventional care is authorized.

    • Documented trial of conservative measures (e.g., medications, physical therapy, activity modification) is required prior to many interventions
    • For facet IA injections: 6-week medication trial and 6-week PT/chiropractic trial within last 12 months
    • Custom orthoses: prefabricated orthotics must have been tried and failed unless custom need is documented (contracture, deformity, abnormal limb contour, minimal muscle mass, etc.)
    • TMJ: trial of up to a total of four PT/OT visits related to TMJ condition; intra-oral appliance prolonged use requires documentation of 1-year trial failure/contraindication
    • Microprocessor-controlled prosthetics: patient must have used a standard lower limb prosthesis for minimum three months and meet rehabilitation/prosthetist documentation requirements
    Billing Rule

    Order and therapy documentation requirements; modifier-based billing rule

    Therapy orders and session documentation must include a Plan of Care (POC), evaluation, treatment session notes, and discharge criteria when indicated; detailed session-level documentation is required and billing must reflect active treatment.

    • POC must include functional/physical impairments, measurable short- and long-term goals, treatment frequency/duration, and anticipated session length
    • Progress notes must document date, specific treatments matching CPT codes billed, session length, patient response, skilled reassessment, objective progress toward goals, problems/POC changes, caregiver/home program involvement, and provider signature/date
    • Reimbursement limited to maximum 60 minutes per date of service; prior authorization required for PT (after 10 visits) and other therapies (after 8 visits) for medical necessity review
    • Spinal manipulation/chiropractic services must be billed with AT modifier for Active Treatment; absence of AT modifier can result in denial as maintenance care

    Contrast and Imaging Modality Guidance

    Billing Rule

    Non‑contrast MRI allowed for specified trauma/fracture indications

    For trauma/fracture imaging, non‑contrast MRI is considered medically necessary for suspected acute/occult scaphoid, talus, tarsal navicular, and great toe sesamoid fractures and for certain post‑operative evaluations when other findings suggest infection or delayed union/nonunion.

    Billing Rule

    Advanced imaging within 12 months required to show cyst/effusion causing nerve‑root compression

    Evidence of nerve‑root compression from a facet synovial cyst or large effusion must be demonstrated on MRI or CT performed within the previous 12 months and correlate with clinical findings to support intraarticular facet injection.

    Key Definitions and Terms

    MR Elastography — definition and context
    DefinitionMR Elastography: noninvasive MRI technique to assess hepatic fibrosis in chronic liver disease when moderate/severe hepatic iron overload is absent; indicated when VCTE is unavailable/contraindicated/indeterminate or for NAFLD with suspected fibrosis
    Clinical scenariosApplicable for chronic hepatitis B/C or NAFLD when assessing advanced fibrosis or cirrhosis per listed scenarios
    Contrast to other testsUsed when vibration‑controlled transient elastography is unavailable, contraindicated, or indeterminate
    PET SPN and FDG prostate note
    PET SPN notePET for solitary pulmonary nodule considered when SPN ≥ 8 mm; use of FDG PET for prostate cancer evaluation is considered experimental/investigational and not covered
    Tracer limitationFDG tracer use for prostate cancer evaluation is specifically excluded as experimental
    Clinical implicationOrder PET for SPN only when size threshold met and avoid FDG PET for prostate cancer per policy
    Facet IA repetition — definition
    Repeat definitionFacet IA repetition: a repeat injection at the same anatomic site is allowed only if prior injection produced ≥50% pain reduction with functional improvement lasting at least 3 months; cyst aspiration/rupture may be repeated once within 12 months under same pain relief conditions
    Timing constraintsRepeat injections counted toward the rolling 12‑month maximum of 4 sessions per spinal region
    Documentation requiredPrior imaging correlation and documentation of pain relief and functional improvement required
    WES / WGS — definitions
    WES definitionWhole exome sequencing (WES) selectively analyzes the protein‑coding regions (exons) of the genome; used to identify disease‑causing DNA variants
    WGS contrastWhole genome sequencing (WGS) analyzes both coding and noncoding regions and provides broader genomic information
    Coverage stanceWES/WGS and multigene panels require prior authorization and are generally considered investigational unless approved via prior auth review
    Newly diagnosed GBM — definition
    Newly diagnosed GBMHistologically confirmed WHO grade IV supratentorial astrocytoma treated with maximal debulking when feasible followed by chemotherapy and radiotherapy; TTFT initiated within 7 weeks of last chemo/radiation dose
    Initiation criteriaNo evidence of progression by RANO criteria and Karnofsky Performance Score ≥70 required before TTFT initiation
    Continued useContinued coverage requires in-person re-evaluation and documentation of adherence and benefit between day 60 and 91 after initiation
    Functional ability classification for prostheses (K‑levels)
    Functional classification useFunctional ability classification (K‑levels 0–4) is used to assess medical necessity for prostheses and related device selection
    Levels 0–2 summaryLevel 0: no ambulation potential; Level 1: transfers/household ambulation at fixed cadence; Level 2: limited community ambulation over low-level barriers
    Higher levelsLevels 3–4 denote community ambulation with variable cadence or high‑demand ambulation and are required for many microprocessor devices
    Level 0–4 (K‑level) brief
    K‑level overviewLevel 0: no ambulation potential; Level 1: household ambulator; Level 2: limited community ambulator; Level 3: community ambulator with variable cadence; Level 4: exceeds basic ambulation (high impact/athlete)
    Use caseK‑level determination informs prosthetic device eligibility and selection (e.g., microprocessor knees require K3)
    ConsiderationsBilateral amputees may not fit strict K‑level categorization; functional assessment must be individualized

    Prior Authorization Requirements

    Prior Authorization

    All CT scans require prior authorization

    All CT scans require prior authorization effective 1/1/26; obtain PA before scheduling to comply with payer policy.

    Prior Authorization

    Lab‑based genetic/genomic testing requires prior authorization before completion

    All laboratory‑based genetic/genomic testing requires prior authorization BEFORE testing is completed; do not perform tests prior to receiving PA approval.

    Prior Authorization

    DME prior authorization and single‑purchase limitation (3 years)

    Durable medical equipment prior authorization may be required depending on the plan's dollar threshold; benefits are subject to one purchase per DME type every three years (including repairs/replacements).

    Prior Authorization

    DME/spinal orthoses and TMJ treatments require prior authorization per dollar threshold

    Prior authorization is required for DME, custom spinal orthoses, and TMJ treatments depending on dollar thresholds—verify PA requirements and submit required clinical documentation before dispensing.

    Note

    Imaging for therapy/chiropractic must be supported by H&P; therapy PA rules apply separately

    Imaging ordered to support therapy or chiropractic services must be supported by history and physical exam; separate therapy prior authorization rules (visit limits, documentation) apply to therapies referenced in imaging requests.

    Background and Scope

    This policy update clarifies and expands imaging indications and utilization controls. Key changes include expanded MRI indications across body regions (for example, abdominal MRI for iron overload and added MR elastography criteria), stricter documentation requirements for repeat MRI within 6 months, a new operational prior authorization requirement for all CT scans effective 1/1/26, refined PET exclusions (including FDG tracer for prostate cancer), limits on image‑guided facet injections (frequency and per‑session level caps), new prior authorization and denial rules for genetic/genomic testing, neuropsychological testing hour limits, and tightened DME/prosthesis replacement and custom orthosis documentation requirements.

    Policy Revision History

    2026-01-01operationalLatest

    All CT scans require prior authorization effective 1/1/26; clinical and administrative denial risks for CT without prior authorization noted.

    2025-09-01clinical_addition

    Multiple MRI indications added or clarified (abdomen evaluation for iron overload; MR elastography for chronic liver disease; MRI breast, pelvis, upper/lower extremity trauma, TMJ, internal auditory canal); repeat MRI within 6 months requires case-by-case justification with submission of most recent imaging report and one qualifying justification.

    2025-09-01clinical_addition

    Non-contrast MRI for certain acute/occult fractures and post-operative complications added; meningioma surveillance imaging intervals specified.

    2025-09-01clinical_change

    PET solitary pulmonary nodule evaluation threshold added (SPN must measure ≥ 8 mm) and use of FDG PET for prostate cancer labeled experimental/investigational (not medically necessary).

    2025-09-01clinical_change

    Epidural and facet injection policies revised: interlaminar ESI limited to a single vertebral level; intraarticular (IA) facet injections require documented 6-week medication and 6-week PT/chiropractic trials and meet one of enumerated conditions; IA facet frequency limited to maximum of 4 sessions per spinal region per rolling 12 months and maximum 2 levels per session.

    2025-09-01clinical_addition

    Genetic and genomic testing (including multigene panels, WES/WGS) require prior authorization before testing and are generally considered experimental/investigational unless approved via prior auth review.

    2025-09-01clinical_addition

    Neuropsychological testing: 'complicated ADHD' indication added; computerized cognitive testing devices and testing >10 hours considered experimental/not medically necessary.

    2025-09-01clinical_change

    Tumor treating fields (TTFT) coverage limited to newly diagnosed GBM with requirements for initiation and continued coverage including in-person re-evaluation between day 60 and 91 and objective adherence evidence; continued use review interval changed to every 3 months.

    2025-09-01policy_addition

    Prior authorization requirements added or clarified for TMJ treatments, DME (depending on dollar threshold), PT/OT/ST (PA after visit thresholds effective 1/1/26), and prosthesis replacement/repair timing (replacement limited to no sooner than every 3 years; irreparable wear replacement not less than 5 years).

    2025-09-01coverage_update

    Custom orthoses and spinal orthoses coverage criteria clarified; reasonable useful lifetime of custom fabricated orthosis set to 3 years and single-purchase limitation for a type of DME every 3 years.

    2025-09-01coverage_update

    Microprocessor-controlled and powered lower-limb prosthetic criteria and K-level prerequisites defined, including daily ambulation and trial requirements.

    2025-09-01coverage_change

    Therapy visit authorization and reimbursement limits added: prior authorization after 10 PT visits (after 8 for other therapies) and reimbursement capped to one hour per date of service effective 1/1/26.

    2025-09-01removal

    Prior authorization requirement for Spinal Manipulation Treatments and Chiropractic Treatments was removed (operational change announced with revised effective dates).

    2025-09-01eiu_list_additions

    Numerous devices and procedures were added to the Experimental/Investigational/Unproven list (e.g., LimFlow, various devices, low-level laser therapy, Sustained Acoustic Medicine).

    2025-09-01coverage_change

    Use of TENS and several modalities reclassified as experimental/investigational and not medically necessary across applicable policies.

    2025-09-01administrative

    Policy effective dates adjusted: certain policies moved from 12/1/25 to 1/1/26 per revised version announcement.